Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.630

-1.3%

Jan 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (456)	12/22/2005 4:48:40 PM
From: Jibacoa	Read Replies (2) of 802

Perhaps Zeta knows, based on studies posted here. Don't count on her for that, she is still suffering from jet lag.<g> I don't see why they will have to pay a statistical penalty since the FDA has suggested to perform interim efficacy analyses of the P3 and INGN claims to have a plan to carry them out consistent with the FDA initiatives. But as you said, will have to wait for the results of that interim analysis to become available. I would like to see ADVEXIN approved, but my expectations are better for INGN241 and others that they have, including INGN 234, which is the one on their deal with Colgate.<g> The stock's support is now at 5.10 and resistance at 6.80, but I don'y expect much to happen until the stock can close above its July 21 H of 7.40 <g> bigcharts.marketwatch.com RAGL Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next